New drugs and treatment regimens

Derek J. Sloan, Geraint R. Davies, Saye H. Khoo

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.

Original languageEnglish
Pages (from-to)200-210
Number of pages11
JournalCurrent Respiratory Medicine Reviews
Issue number3
Publication statusPublished - 2013


  • Bedaquiline (TMC-207)
  • Delamanid (OPC-67683)
  • Gatifloxacin
  • Moxifluxacin
  • PA-824
  • Rifampicin
  • Rifapentine
  • Sterilising activity


Dive into the research topics of 'New drugs and treatment regimens'. Together they form a unique fingerprint.

Cite this